Label-Free Whole-Body Pharmacokinetics

Understanding drug pharmacokinetics at the tissue level—beyond what traditional plasma bioanalysis reveals—is essential for developing safer, more effective therapies. While Quantitative Whole-Body Autoradiography (QWBA) has long been a standard in the pharmaceutical industry, its high cost and limited molecular specificity make it less suitable for early-stage evaluation of drug distribution and metabolites.

In this session, Aliri Lab Director Mathieu Gaudin, Ph.D., joins Hervé Giorgi, Ph.D., Non-clinical Development Director at Genfit, to discuss how Mass Spectrometry Imaging (MSI) of whole-body mice offers a powerful, label-free alternative for early-phase pharmacokinetic studies. This innovative approach enables comprehensive tissue-level analysis, delivering critical insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection—faster and more cost-effectively than traditional methods.

Key takeaways include an overview of whole-body pharmacokinetics and its benefits, a deep dive into how this new method drives informed decision-making, and a real-world look at how Genfit has integrated this technology into their development strategy.